Combination immune therapy for type 1 diabetes

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/2000367

Funding Status
Status not available

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

This clinical trial will test whether a combination of two safe therapies, abatacept and nasal insulin, can stop the immune attack that causes type 1 diabetes. Sixty-two children and young adults with recently-diagnosed type 1 diabetes will receive either abatacept and nasal insulin or abatacept and nasal placebo for one year to determine if combined immune therapy preserves pancreas function and decreases the need for insulin therapy.

Funded Activity Details

Start Date: 01-01-2021

End Date: 01-01-2025

Funding Scheme: Clinical Trials and Cohort Studies Grants

Funding Amount: $1,803,802.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

immune modulation | immune tolerance | metabolic control | type 1 diabetes mellitus (insulin-dependent diabetes mellitus)

Related Links